Acute Leukemia – Relapsed/Refractory

Genetic mutation/target

- Wild-Type TP53
  - IRB# 16338: Phase 1/1b ALRN-6924 alone, in combination with Ara-C

- Wild-Type TP1
  - IRB# 7195: Phase 2 Kinase Inhibition, individualized targeted therapies
  - IRB# 17379: Phase 2b, study of PDR001 and/or MBG453 in combination with decitabine

No specific mutation/target

- IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

Post-transplant

- IRB# 15993: HLA-A2.01 and PRAME
  - IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

Studies Coming Soon for no specific mutation/target:
- IRB# 15588 (SMMART Trial)
  - IRB# 19908: A Phase ½ Galinpepimut-S in combination with Pembrolizumab
  - IRB# 19290
  - IRB# 19339
  - IRB# 18253

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php